18279004. LIPOSOMAL FORMULATIONS OF BORONIC ACID CONTAINING ACTIVE AGENTS simplified abstract (OHIO STATE INNOVATION FOUNDATION)
Contents
- 1 LIPOSOMAL FORMULATIONS OF BORONIC ACID CONTAINING ACTIVE AGENTS
- 1.1 Organization Name
- 1.2 Inventor(s)
- 1.3 LIPOSOMAL FORMULATIONS OF BORONIC ACID CONTAINING ACTIVE AGENTS - A simplified explanation of the abstract
- 1.4 Simplified Explanation
- 1.5 Potential Applications
- 1.6 Problems Solved
- 1.7 Benefits
- 1.8 Potential Commercial Applications
- 1.9 Possible Prior Art
- 1.10 Unanswered Questions
- 1.11 Original Abstract Submitted
LIPOSOMAL FORMULATIONS OF BORONIC ACID CONTAINING ACTIVE AGENTS
Organization Name
OHIO STATE INNOVATION FOUNDATION
Inventor(s)
Robert Lee of Lewis Center OH (US)
LIPOSOMAL FORMULATIONS OF BORONIC ACID CONTAINING ACTIVE AGENTS - A simplified explanation of the abstract
This abstract first appeared for US patent application 18279004 titled 'LIPOSOMAL FORMULATIONS OF BORONIC ACID CONTAINING ACTIVE AGENTS
Simplified Explanation
The patent application describes a liposomal formulation for the improved delivery of boronic acid esters of boronic acid therapeutic agents. The formulation includes liposomes formed from a vesicle-forming lipid and a capturing agent-active agent complex encapsulated in the liposomes.
- Liposomal formulation for improved delivery of boronic acid esters of boronic acid therapeutic agents
- Liposomes formed from a vesicle-forming lipid
- Capturing agent-active agent complex encapsulated in the liposomes
Potential Applications
The technology could be applied in the pharmaceutical industry for the targeted delivery of boronic acid therapeutic agents, potentially improving their efficacy and reducing side effects.
Problems Solved
1. Enhanced delivery of boronic acid esters of boronic acid therapeutic agents 2. Targeted delivery to specific cells or tissues
Benefits
1. Improved efficacy of boronic acid therapeutic agents 2. Reduced side effects 3. Targeted delivery for better treatment outcomes
Potential Commercial Applications
"Targeted Delivery of Boronic Acid Therapeutic Agents Using Liposomal Formulation"
Possible Prior Art
There may be prior art related to liposomal formulations for drug delivery, especially in the field of cancer treatment where targeted delivery is crucial.
Unanswered Questions
How does the liposomal formulation compare to other drug delivery methods in terms of efficiency and safety?
The article does not provide a direct comparison with other drug delivery methods, leaving a gap in understanding the advantages of this specific formulation.
Are there any limitations or challenges in scaling up the production of this liposomal formulation for commercial use?
The scalability and production challenges of this technology are not addressed in the article, leaving room for further investigation into its practical applications.
Original Abstract Submitted
Described are liposomal formulation for the improved delivery of boronic acid esters of boronic acid therapeutic agents. The liposomal formulation can include (i) liposomes formed from a vesicle-forming lipid; and (ii) a capturing agent-active agent complex encapsulated in the liposomes.
